In the News

Two-year $300 Million Extension of the Special Diabetes Program Allows for the Continuation of Promising Ongoing Clinical Trials
April 20, 2015

The U.S. Senate overwhelmingly approved legislation last night for a two-year extension of the Special Diabetes Program (SDP)—an initiative that accounts for roughly one-third of all Federally-funded type 1 diabetes (T1D) research in the United States. The decision comes on the heels of the strong bipartisan approval of the legislation on March 26 by the U.S. House of Representatives, and will extend SDP funding for the National Institutes of Health (NIH) at the current level of $150 million, per year, as part of the ‘Medicare Access and CHIP Reauthorization Act of 2015’ (H.R. 2). The President is expected to sign the legislation into law today.

Read More
REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells
April 15, 2015

REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI’s proprietary αGalCer/liposome platform for immunological tolerance for the treatment of type 1 diabetes (T1D). Under the terms of the collaboration, REGiMMUNE will develop an antigen-specific therapeutic liposome that potentially prevents or delays the onset of T1D and induce immunologic tolerance. 

Read More
JDRF in the Globe and Mail, April 1, 2015: Improving the chances for healthy pregnancies.
By JDRF Canada
April 1, 2015

JDRF showcases the CONCEPPT trial, including quotes from Dr. Lois Donovan, Medical Director of diabetes in pregnancy in Calgary - Alberta Health Services and Dr. Helen Murphy in Cambridge, U.K., who are co-principal investigators overseeing Canadian and international sites. The story also provides a trial patient perspective and her experience.  And last but not least, a great segment on JDRF CCTN and a quote from Minister Gary Goodyear supporting JDRF’s efforts.

Read More
Stem cells show promise for reversing Type 2 diabetes
By The University of British Columbia
March 25, 2015

Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs.

Read More
Tags: ViaCyte, Health Canada, Clinical Trials
JDRF Announces New Partnership with the European Foundation for the Study of Diabetes and Eli Lilly and Company to Fund Novel Diabetes Research
March 9, 2015

JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research announced today a new research partnership with the European Foundation for the Study of Diabetes (EFSD) and Eli Lilly and Company to establish a new research funding program to accelerate type 1 diabetes discovery and translational research.

Read More